LIVINGSTONE HEALTH HOLDINGS LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration Number 200404283C)

PROPOSED PLACEMENT OF UP TO 55,557,000 NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY AT THE PLACEMENT PRICE OF S$0.027

- **COMPLETION OF THE PROPOSED PLACEMENT**

The board of directors (the "**Board**" or "**Directors**") of Livingstone Health Holdings Limited (the "**Company**" and together with its subsidiaries, the "**Group**") refers to the Company's announcements dated 9 February 2024 and 15 February 2024 in relation to the Proposed Placement of up to 55,557,000 Placement Shares at the Placement Price of S$0.027 for each Placement Share pursuant to the Placement Agreement entered into with SAC Capital Private Limited as the Placement Agent.

Unless otherwise defined, capitalised terms used in this announcement shall have the same meaning given to them in the Company's announcement dated 9 February 2024.

The Board is pleased to announce that in accordance with the terms and conditions of the Placement Agreement, the Company has received the aggregate consideration of S$1,500,039 from the Placement Agent. Accordingly, the Company has on 22 February 2024 allotted and issued all 55,557,000 Placement Shares, and the Proposed Placement is completed.

Following the allotment and issuance of the Placement Shares, the total number of issued Shares (excluding treasury shares and subsidiary holdings) of the Company has increased from 436,391,448 Shares to 491,948,448 Shares. The Placement Shares that are issued are free from all claims, pledges, mortgages, charges, liens and encumbrances and rank in all respects *pari passu* with the existing Shares of the Company, except that the Placement Shares will not rank for any dividends, rights, allotments or other distributions, the record date for which falls on or before the date of allotment and issue of the Placement Shares.

The Placement Shares are expected to be listed and quoted on the Catalist of the SGX-ST on or around 26 February 2024.

By Order of the Board

Dr Tay Ching Yit, Wilson
Executive Director and Chief Executive Officer
22 February 2024

---

*This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited (the "**Sponsor**"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Lee Khai Yinn (Telephone: (65) 6232 3210) at 1 Robinson Road, #21-00, AIA Tower, Singapore 048542.